This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
No details relating to the comparability of the groups or adjustment for confounding factors were provided. The authors did not state whether the analysis was conducted on an intention to treat basis or on treatment completers only. The outcomes estimated were: the distributions of the annual frequency and the severity of migraine attacks; the duration of the symptoms per attack; the time missed from paid work activities; the time lost from paid work activities due to reduced effectiveness; and the medication taken to treat symptoms.
The annual frequency of migraine attacks was derived using log-normal probability distributions for men and women. It was fitted to the patients' reported history of attacks at screening. The severity of the attacks was derived from the distribution observed during the trial in men and women, for the naratriptan and customary therapy groups. The probability distributions for the duration of symptoms per attack were calculated according to gender, treatment, and severity of attack. Time-lost distributions were calculated according to treatment and severity. Distributions for nonwork time lost were estimated separately for employed and unemployed migraineurs. The number of doses taken per attack, and the type of medications used for each severity level, were also estimated.
Effectiveness results
Men had a mean annual attack rate of 37.9 (standard deviation 23.3), while women had an attack rate of 34.8 (standard deviation 18.8).
Men rated more migraines as mild (25.3% in the naratriptan group and 25.6% in the customary therapy group) than did women (15.2% in the naratriptan group and 15.3% in the customary therapy group).
Women rated more migraines as severe (33.7% in the naratriptan group and 34.3% in the customary therapy group) than did men (24.0% in the naratriptan group and 27.3% in the customary therapy group).
Compared with customary therapy (not including triptans), naratriptan led to an annual reduction in symptom duration of 225 hours per patient (37% reduction).
The time lost due to migraine decreased from 117.5 hours with customary therapy to 75 hours with naratriptan.
The other outcomes were not reported numerically.
Clinical conclusions
Naratriptan led to a 37% reduction in the annual duration of migraine symptoms and a reduction in the time lost due to migraine.
Modelling
A Monte Carlo model was used to simulate a migraineur population with a given set of characteristics (age, gender and employment status). It also simulated their migraine experience over the course of one year, including the severity and duration of the migraine attacks, the days on which the attacks happen, and other related health care used. The model processed 10,000 simulated Canadian migraineurs treated with customary therapy and with naratriptan therapy to evaluate the benefits and the costs.
Measure of benefits used in the economic analysis
The measures of benefits used in the economic analysis were the annual duration of migraine symptoms and the activity time lost.
Direct costs
The costs of medications, migraine-related physician visits, emergency department visits, and hospitalisations were analysed. For customary therapy, only those medications used by Canadian participants were included in the analysis. The drug costs were as listed in the Canadian provincial drug formularies. The health care costs were derived using data from the Ontario Case Costing Project (1994 Project ( to 1996 , Statistics Canada, a report by the Canadian Co-ordinating Office for Health Technology Assessment, and a published profile of emergency department costs by diagnosis. Discounting was irrelevant as the study was carried out over a period of one year. The cost data from before 1998 were adjusted to 1998 using Canadian consumer or health care price indexes.
Statistical analysis of costs
Not conducted.
Indirect Costs
The indirect costs included the cost of time lost from paid work, based on average hourly wages (Statistics Canada earnings information). The wages for part-time employees were assumed to be 20% lower than the wages for full-time employees. The cost of time lost from unpaid work activities was derived from Statistics Canada estimates. No cost for the leisure time lost was incorporated. Discounting was irrelevant as the study was carried out over a period of one year.
Currency
Canadian dollars (Can$).
Sensitivity analysis
Sensitivity analyses were conducted to investigate the following: the costs of paid, unpaid and leisure time lost; the cost of naratriptan; non-prescription medical costs; and the effectiveness of naratriptan in reducing the time lost.
Analyses were also performed in which only severe migraine attacks were treated with naratriptan, and in which attacks of all severities were treated with naratriptan.
Estimated benefits used in the economic analysis
Naratriptan use led to a 37% reduction in the annual duration of symptoms. This corresponded to 225 hours per patient (from 608.4 hours with customary therapy to 383 hours with naratriptan).
The annual time lost from work was 51.4 hours with customary therapy and 32.8 hours with naratriptan. The annual time lost from unpaid work was 19.9 hours with customary therapy and 12.6 hours with naratriptan. The annual leisure time lost was 46.2 hours with customary therapy and 29.6 hours with naratriptan. Thus, the overall time lost due to
